Real-world data on the efficacy and safety of pazopanib in IMDC favorable- and intermediate-risk metastatic renal cell carcinoma: a multicenter retrospective cohort study of Chinese patients

BACKGROUND: Pazopanib was recommended as first-line treatment option for Metastatic renal cell carcinoma (mRCC), while evidence from strictly selected patients has poor external validity and clinical characteristics are complex in real-world clinical practice. This study aimed to illustrate the surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Anwaier, Aihetaimujiang, Chen, Jianhui, Zhou, Hongfeng, Zhao, Xinxin, Zheng, Song, Li, Xiaofan, Qu, Yuanyuan, Shi, Guohai, Zhang, Hailiang, Wu, Jin, Ye, Dingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177258/
https://www.ncbi.nlm.nih.gov/pubmed/35693709
http://dx.doi.org/10.21037/tau-22-312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177258/
https://www.ncbi.nlm.nih.gov/pubmed/35693709
http://dx.doi.org/10.21037/tau-22-312

Ejemplares similares